I n this issue of American Journal of Hypertension, Wu et al. show that aspirin (ASA) treatment of wild-type (WT) and COX-1 −/− mice attenuated the hypertensive response to angiotensin II (AII) as well as basal and AII-stimulated superoxide production. 1 These effects were attributed to inhibition of COX-2 as basal and AII-stimulated superoxide generation and blood pressure (BP) elevation were lower in COX-2 −/− mice. 1 While this interpretation is valid, it is possible that the effects of ASA result from antioxidative effects rather than inhibition of COX-2. 2 These possibilities might have been addressed had a selective inhibitor of COX-2 been employed in the WT and COX-1 −/− mice. Nonetheless, there is evidence for stimulation of NADPH oxidase by COX-2 3 and an inhibitor of COX-2 prevented the increase in superoxide from microvascular endothelial cells exposed to high glucose. 4 Also, in the COX-2 −/− mouse, it would be interesting to test the effects of a selective COX-1 inhibitor, although the combination might prove lethal, as was the case with ASA.
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A concern with this study is that renal injury resulting from COX-2 deletion may be responsible for the reduced response to AII as these mice exhibit progressive insufficiency associated with elevation of BP at 8 weeks of age. However, at 5 weeks of age, superoxide formation and BP of the COX-2 −/− mice were not different from those of WT or COX-1 −/− mice. These observations suggest that the changes in the response to AII are secondary to the COX-2 −/− phenotype rather than a direct effect of COX-2 removal and question the contribution of COX-2 to oxidative stress and the hypertensive response to AII in this model. Thus, if COX-2 is the source of basal superoxide generation, it is difficult to explain why it would not be reduced throughout life rather than a deficit appearing after 5 weeks of age. To address the role of COX-2 in the absence of renal impairment, perhaps a conditional knockout should be used where COX-2 is eliminated at 5 weeks of age.
Deletion of COX-2 has been reported to reduce plasma renin levels and the resultant decrease in AII could explain reduced superoxide generation. Moreover, a deficiency of AII in the COX-2 −/− mice might be expected to lead to upregulation of AT1 receptors and enhanced pressor responses to AII as reported by Qi et al. in female mice. 5 The contrasting results of this study where reduced pressor responses to AII were observed in male COX-2 −/− mice raise the question of gender differences that may be reflected in the susceptibility to renal insufficiency resulting from COX-2 deletion. Thus, Qi et al. reported no elevation of BP or renal insufficiency in the female COX-2 −/− mice unlike the male mice used in this study. Interestingly, Yang et al. reported that elevation of BP and albuminuria were greater in male vs. female 129/Sv COX-2 −/− mice. 6 However, gender differences may not account for the contrasting pressor response to AII in COX-1 −/− mice in this study vs. 
